Sanofi India is divesting its insulin brand, Lantus, with Glenmark, Dr. Reddy's, and Emcure Pharma considering acquisition, though a licens...

Lupin's subsidiary, in partnership with ImpiloVest, has acquired nine brands from MNI in South Africa, enhancing its portfolio in complemen...

Eris acquired Biocon Biologics' domestic branded formulation business for Rs 1,242 crore in Q4FY24 and dermatology and nephrology units in ...

As part of the deal over 430 employees associated with the business are expected to transition to Eris, ensuring continuity for both employ...

"Cipla historically has always been a big respiratory and acute player but not that big in the diabetes area," said Umang Vohra, managing d...

Eris Lifesciences, incorporated in the year 2007, is a Mid Cap company (having a market cap of Rs 8701.37 Crore) operating in Pharmaceutica...

Improving prospects of the pharma industry, growth in the global generics market, expanded product portfolio and cost reduction initiatives...

The launch of long acting insulin glargine will help Eris to fill the gap in its insulin portfolio. Eris derives more than half of its reve...

BBL said the cash payment of $2 billion to be funded by $800 million raised through equity infusion in BBL and the remainder to be funded b...

Eye minority stake in Biocon Biologics; unit may be valued at $4 billion, higher than the market cap of Biocon.

Sources say cos have already signed a business transfer deal for the domestic women healthcare portfolio, which is worth around Rs 300 cror...

The Ranbaxy brands that Sun is looking to sell rake in about Rs 115 crore in annual sales and the company is expecting a valuation of about...

French drug maker Sanofi says it is considering an India-specific strategy to increase its share in the country’s Rs 65,000-crore drug mark...

For a fairly consistent performer in terms of top line growth in the pharma industry, drug maker Lupin’s show in the quarter to December wa...

Unlike other foreign drugmakers, it plans to stay away from acquisition of local firms or branded generics to boost its market share.

Biotechnology major Biocon's net profit for the fourth quarter rose sharply after revenues increased and a forex loss of Rs 41.4 crore had ...

India's top biotechnology firm, Biocon Ltd, is looking at overseas acquisitions for about $10 million to boost its sales globally and gain ...